Ann: Positive Safety Data from Phase 1 Clinical Trial, page-53

@RED328

That’s an outrageouspost. I’ll raise you.
If we’re going to evaluate the possible market cap or takeover for RCE. Let’s usenumbers…

R327 by statistics has roughly a 6-7% chance of making it through to FDA approval.

Phase 1 (Approximately 70% of drugs move to the next phase)

Phase 2 (Approximately 33% of drugs move to the next phase)

Phase 3 (Approximately 25-30% of drugs move to the next phase)

The Recce Equity Research report states that they R327 will be sold at USD 5000 a therapeutical treatment for Sepsis and USD500 for burns application.

In 2004, Nearly 11 million people worldwide were burned severely enough to require medical attention (World Health organisation) $500 x 11,000,000 = $5.5 billion
Data from 2017 show that sepsis affected 49 million people and was linked to approximately 11 million deaths world wide - roughly 20% of annual global deaths. $5000 x 11,000,000 = $55 billion. Remember that sepsis is the number 1 most expensive condition to treat in the entire U.S health care system. In 2013 it cost the US $24 Billion dollars. That’s the US alone.

Add those numbers together and we get $60.5 billion. Even if Recce managed to get 10% of the market on a conservative account its still $6.05 $billion dollars a year.

CSL in 2019 reported 8.53 billion USD is revenue. Its market cap at that time was $89.50 Billion
So let’s just say revenue is roughly 10% of a pharmaceutical company market cap (these are very, very loose figures)

RCE, if we get marketable applications for Sepsis and Burns would give us 6.05 billion dollars in revenue. Remember that R327 cost near nothing to produce and has no expensive waste products. This would put our market cap at 60.5billion USD. 60,500,000,000 / 176,000,000 Shares on offer
$343.75 a share. But we’ve got roughly 6-7% of that happening, and it’s going to take a decade.

The potential for RCE is uncapped. I struggle to understand why we currently have the market cap we do